Highest-materiality recent filing
BBWI Q1 sales down 3%, adjusted EPS $0.32 beats guidance; CFO Boratto to step down June 12
Q1 net sales $1.378B (-3% YoY); GAAP EPS $0.90, adjusted EPS $0.32 (beating guidance).
BBWI Q4 adj EPS $2.05 beats; FY2026 sales guide down 2.5-4.5%, adj EPS $2.40-2.65
Q4 net sales $2.724B (-2% YoY); adj EPS $2.05 vs prior year $2.09 but above company guidance.
Bath & Body Works launches transformation plan; Q3 EPS $0.37, cuts FY25 guidance
Q3 net sales $1.594B (-1% YoY); GAAP EPS $0.37 ($0.35 adj); operating income $161M vs $218M prior year.
BBWI Q2 net sales +1.5% to $1.55B, adj EPS $0.37 (high end); raises FY adj EPS low end
Q2 GAAP EPS $0.30 vs $0.68 last year; adj EPS $0.37 flat YoY.
Bath & Body Works Q1 net sales up 3% to $1.42B, EPS up 29% to $0.49; maintains FY guidance
Net sales $1,424M (+2.9% YoY); EPS $0.49 (+29% YoY) vs $0.38 prior year.
Bath & Body Works names Daniel Heaf CEO; Q1 EPS $0.49 beats high-end guidance
Daniel Heaf appointed CEO effective May 16, 2025, replacing Gina Boswell who stepped down.
Bath & Body Works Q4 2024 beats guidance; provides FY2025 outlook
Q4 net sales $2,788M (down 4.3% YoY on 13 vs 14 weeks); GAAP EPS $2.09 vs $2.55.
Bath & Body Works redeems all outstanding 9.375% Senior Notes due 2025 on Jan 30
Notice of redemption for any and all outstanding 9.375% Senior Notes due 2025.
Bath & Body Works Q3 sales up 3% to $1.61B, EPS $0.49 beats guidance; raises FY guidance
Q3 net sales $1,610M (+3% YoY); EPS $0.49 vs $0.52 ($0.48 adjusted) prior year, exceeding guidance.
Bath & Body Works Q2 adjusted EPS $0.37 beats guidance; lowers FY2024 outlook
Q2 net sales $1,526M, down 2.1% YoY; adjusted EPS $0.37 vs. $0.40 last year, above guidance.
Bath & Body Works Q1 EPS $0.38 beats high-end guidance; narrows FY2024 range upward
Q1 net sales $1,384M (-0.9% YoY) above guidance; diluted EPS $0.38 (GAAP), up 9% YoY.
BBWI Q4 EPS beat; new $500M buyback; FY2024 sales guidance -3% to flat
Q4 net sales $2.912B (+0.8% YoY; extra week contributed ~$80M); adjusted EPS $2.06 vs guidance $1.87.
Bath & Body Works beats Q3 EPS guidance; raises FY2023 adj. EPS midpoint
Q3 net sales $1.562B, down 2.6% YoY; GAAP EPS $0.52 vs $0.40 prior year.
Bath & Body Works Q2 sales down 3.6% to $1.559B, adj EPS $0.40 beat; FY guide raised
Net sales $1.559B (-3.6% YoY), in line with expectations.
Bath & Body Works Q1 EPS beats guidance; full-year EPS outlook raised
Q1 net sales $1.396B, down 4% YoY; EPS $0.35 vs $0.64 prior year.
Wendy Arlin to step down as CFO effective July 29, 2023 or earlier if successor named; search initiated.
Bath & Body Works appoints Thomas J. Kuhn to board; Third Point drops proxy contest
Thomas J. Kuhn appointed as independent director effective March 10, 2023; brings 35 years of financial and legal advisory experience.
Bath & Body Works Q4 sales down 5% to $2.889B; EPS $1.86 vs $2.27; guides FY23 EPS $2.50-$3.00
Q4 net sales $2.889B (-5% YoY); operating income $652.7M vs $879.2M; net income $428.2M vs $592.6M.
Bath & Body Works Q3 EPS $0.40 beats guidance; raises FY2022 EPS outlook
Q3 net sales $1.60B, down 5% YoY from $1.68B; EPS $0.40 vs guidance of $0.10-$0.20.
Bath & Body Works appoints Gina Boswell as CEO effective December 1, 2022
Gina Boswell named CEO and board member; starts December 1, 2022.
Bath & Body Works Q2 EPS $0.52, sales down 5%; COO resigns, 130 roles cut
Q2 net sales $1.618B (-5% YoY); diluted EPS $0.52 vs $0.77 prior year.
Bath & Body Works lowers Q2 and FY 2022 guidance on inflation pressure
Q2 sales now expected down 6-7% YoY vs prior guide of low single-digit increase.
Bath & Body Works beats Q1 guidance but cuts FY2022 EPS outlook to $3.80-$4.15
Q1 net sales $1.450B (-1% YoY); adjusted EPS $0.64 (+7% YoY), ahead of guidance.
CEO Meslow steps down for health; Sarah Nash named interim CEO
Andrew Meslow resigned as CEO and director on May 12, 2022 due to health; Executive Chair Sarah Nash appointed interim CEO.
CEO Andrew Meslow to depart May 12; receives $7M severance, extended non-compete
CEO Andrew M. Meslow resigns effective May 12, 2022 due to health reasons.
CEO Andrew Meslow will step down effective May 12, 2022 due to health reasons; remains CEO through that date.
BBWI reports record Q4/FY21 earnings, CEO Meslow to step down in May due to health
Q4 net sales $3.027B (+11% YoY); GAAP EPS $2.27, adjusted EPS $2.30 (+17% YoY).
Bath & Body Works enters $1 billion accelerated share repurchase with JPMorgan
Agreement with JPMorgan to repurchase $1 billion of BBWI common stock, announced February 2, 2022.
Bath & Body Works Q4 record sales $3.027B (+11%); EPS ~$2.25; $1.5B buyback & 33% dividend hike
Q4 net sales $3.027B, up 11% YoY; expected EPS $2.25 (guidance $2.10-$2.25).
the Board of Directors (the "Board") of the Company approved the appointment of Tom Javitch to serve as the Company’s Interim Chief Financial Officer
Ms. Boratto provided notice of her intent to resign from the Company to pursue another professional opportunity, effective as of the Transition Date, on May 20, 2026.
resigned as a member of the Board effective the same day
the Board of Directors of the Company (the “Board”) has appointed Daniel Heaf to serve as Chief Executive Officer of the Company, effective May 16, 2025
Gina Boswell ceased to serve as Chief Executive Officer of the Company effective as of May 16, 2025
Mr. Heaf will be appointed as a member of the Board effective as of immediately following the conclusion of the Company’s 2025 Annual Meeting of Shareholders
Effective on January 31, 2025, Deon Riley ceased to serve as Chief Human Resources Officer of Bath & Body Works, Inc.
Julie Rosen ceased to serve as President, Retail of Bath & Body Works, Inc. (the “Company”) on September 25, 2024.
On April 20, 2024, Thomas J. Kuhn notified the Board of Directors (the “Board”) of Bath & Body Works, Inc. (the “Company”) of his resignation of service as a director of the Company, effective the same date.
each of Patricia S. Bellinger and Michael G. Morris notified Bath & Body Works, Inc. (the “Company”) of their decision not to stand for re-election to the Company’s Board of Directors following expiration of their current term at the Company’s 2024 Annual Meeting of Stockholders.
each of Patricia S. Bellinger and Michael G. Morris notified Bath & Body Works, Inc. (the “Company”) of their decision not to stand for re-election to the Company’s Board of Directors following expiration of their current term at the Company’s 2024 Annual Meeting of Stockholders.
Wendy C. Arlin will cease serving as Chief Financial Officer effective as of July 29, 2023.
Max materiality 0.85 · Median 0.65 · Most common event earnings